

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Single Technology Appraisal**

**Equality impact assessment – Scoping**

**Tafamidis for treating transthyretin amyloid cardiomyopathy [ID6327]**

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

<p>1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?</p>	<p>It was raised during the scope consultation that the Val122Ile variant of transthyretin amyloid cardiomyopathy (ATTR-CM) is most common in people with African or Caribbean family background. It was also highlighted that this population is often diagnosed later and has worse outcomes than other ATTR-CM patients.</p>
<p>2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?</p>	<p>The committee should be aware that making recommendations for particular subgroups (including for people with Val122Ile mutation) may discriminate against certain people with protected characteristics. This should be taken into account when considering any possible subgroup analyses.</p>
<p>3. Has any change to the draft scope been agreed to highlight potential equality issues?</p>	<p>Yes. The background section of the scope has been updated to acknowledge that the Val122Ile mutation is most common in people with African or Caribbean family background.</p>

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No.

**Approved by Associate Director (name):** ...Linda Landells

**Date:** 31 August 2023